Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial

This 5-year follow-up of a phase 2 clinical trial assesses long-term durability of minimal residual disease–negative remission and time to disease progression among patients with newly diagnosed multiple myeloma who received triplet-based induction therapy with lenalidomide maintenance therapy.

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Oncol
Glavni autori: Kazandjian, Dickran, Korde, Neha, Mailankody, Sham, Hill, Elizabeth, Figg, William D., Roschewski, Mark, Landgren, Ola
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2018
Teme:
Research Letter
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440717/
https://ncbi.nlm.nih.gov/pubmed/30477009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5457
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items